Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience. The company operates primarily in the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on bringing innovative global medicines to patients in China and other Asian markets while also advancing internally developed assets. Its business model combines in-licensed therapies from multinational pharmaceutical partners with proprietary research and development programs.
The company’s primary revenue drivers include product sales from commercialized therapies, milestone payments, and collaboration agreements. Key marketed products and development programs span areas such as lung cancer, ovarian cancer, breast cancer, gastric cancer, epilepsy, and chronic inflammatory diseases. Zai Lab was founded in 2014 by Samantha Du, who established the company to bridge innovative global drug development with unmet medical needs in Greater China. Since its founding, the company has evolved from a licensing-focused biotech into an integrated biopharmaceutical company with commercial infrastructure, manufacturing capabilities, and internal discovery platforms.
Business Operations
Zai Lab operates through integrated research, development, and commercialization activities, with a significant concentration in Greater China. Its business includes internally developed assets as well as collaborations with global pharmaceutical companies. Commercial-stage products and pipeline assets are supported by regulatory, clinical development, medical affairs, and sales operations primarily across mainland China, Hong Kong, Macau, and Taiwan. The company’s operations are commonly organized around therapeutic areas including Oncology, Immunology, Neuroscience, and Infectious Disease programs.
The company controls several strategic assets, including research and translational medicine capabilities, clinical development infrastructure, and manufacturing investments intended to support biologics and advanced therapies. Major partnerships have included collaborations with Novocure, GSK, Bristol Myers Squibb, argenx, and MacroGenics, among others. Through these alliances, Zai Lab has secured regional commercialization or development rights for therapies targeting high unmet-need indications in Asia. Revenue generation has historically been driven by sales of approved products and collaboration-related payments tied to development and regulatory milestones.
Strategic Position & Investments
Zai Lab’s strategy centers on expanding its commercial portfolio while advancing proprietary innovation platforms and late-stage pipeline assets. The company has invested heavily in oncology, including precision medicines, tumor treating fields technology, antibody-based therapies, and targeted therapeutics. It has also pursued expansion into immunology and neuroscience to diversify long-term growth drivers. Public filings and investor materials indicate that management prioritizes accelerating regulatory approvals in China and selectively pursuing global development opportunities for internally discovered candidates.
The company has made substantial investments in R&D infrastructure, manufacturing capabilities, and strategic licensing transactions. Notable portfolio and partnership activity has included rights agreements involving ZEJULA, Optune, VYVGART, and other late-stage assets. Zai Lab has also expanded internal discovery efforts in antibody engineering and cell signaling pathways relevant to cancer and autoimmune diseases. Its positioning is strengthened by experience navigating China’s evolving regulatory environment and by relationships with multinational pharmaceutical companies seeking regional commercialization expertise.
Geographic Footprint
Zai Lab is headquartered in Shanghai, China, with additional operational and corporate presence in Beijing, Suzhou, Guangzhou, Hong Kong, and the United States. The company maintains research, development, and commercial operations primarily across Greater China, while also supporting certain global clinical development initiatives through U.S.-based activities. Its American depositary shares trade on the Nasdaq Global Market, and the company also maintains a listing on the Hong Kong Stock Exchange.
The company’s principal commercial market is China, though its partnerships and clinical development programs have international dimensions involving the United States, Europe, and broader Asia-Pacific regions. Zai Lab’s geographic strategy reflects the growing importance of China in global biopharmaceutical innovation, particularly for oncology and specialty therapeutics. Its operational influence is concentrated in Asia, but many of its collaboration agreements involve multinational development and commercialization structures.
Leadership & Governance
Zai Lab was founded by Samantha Du, who has played a central role in shaping the company’s strategy as an innovation-focused biopharmaceutical enterprise linking global drug innovation with the Chinese healthcare market. The company’s leadership philosophy has consistently emphasized scientific innovation, rapid clinical execution, strategic licensing partnerships, and building long-term commercial infrastructure in Asia. Public company filings and investor communications indicate a governance framework aligned with U.S. and Hong Kong public market standards.
Key executives include:
- Samantha Du – Founder, Chairperson, and Chief Executive Officer
- Josh Smiley – President and Chief Operating Officer
- Ling Zhen – Chief Financial Officer
- Harold Keer, M.D., Ph.D. – President of Research and Development
- Fredi J. Diaz – Chief Legal Officer
- Rafael G. Amado, M.D. – President, Global Research and Development and Head of Oncology Global Development
Information in this overview is based on publicly available disclosures including SEC filings, company annual reports, investor presentations, exchange filings, and reporting from major financial and healthcare industry publications. Where public disclosures differ in terminology or organizational structure, descriptions have been aligned with the most recent available filings.